Kevin Nyango
Biocad is a Russian based company which is making its way to the Moroccan medicine market. Biocab in collaboration with the Moroccan pharmaceutical company Sothema Labs will manufacture a medicine used in treating cancer. The medicine was developed by use of technology given by the Russian firm into the North African market. The production of Russian biosimilars of rituximab and bevacizumab used for cancer treatment will be situated in Morocco.
The biosimilars are to be sold in Gabon, Cote d’Ivoire and Senegal apart from Morocco. The medicine produced by Biocad is in demand in both the developing and developed countries. The first medicine is 30% more expensive than the current medicine to be manufactured. Dmitry Morozov, the CEO of Biocad, lauded the company’s effort and eager in the Moroccan people to bring the production of biosimilars to North Africa which has bared good fruits.
The drugs are expected to be on sale within a short period, and that indicates how the company is capable of competing with the other renowned medicine manufacturers in the world. Biocad is seen as the first company to launch such product in North Africa after the decline by western companies in doing the same. Immediately the company will be in the position to reaching its full production capacity; then the partners expect to take control of more than 50% of the available cancer drugs market.
